What’s In Store For CROs, CDMOs – “Stay In Your Swim Lane”, Consolidation, Divestitures
Executive Summary
Brian Scanlan, operating partner (life sciences), Edgewater Capital Partners, in an interview with Scrip, outlines where things may be headed in the CRO/CDMO segment amid big pharma streamlining efforts, “belt tightening” by emerging biopharma, down rounds and heightened geopolitical tension.
You may also be interested in...
Syngene CEO On Sub-Dynamics As US Biotech Funding Finds New Normal, ADC Capabilities
Syngene’s MD & CEO, Jonathan Hunt, in an interview with Scrip, dissects trends and opportunities in the CRDMO segment as US biotechs slow their burn rate amid a funding squeeze while other large and medium-sized biopharma firms seek to rebalance their supply chain. The Indian firm’s ability to add value in the development and manufacture of ADCs and partnerships with big pharma are some of the other topics the former AstraZeneca executive discussed.
Finance Watch: Lexeo Launches 20th US Biopharma IPO In 2023
Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.
A Gloomy Outlook On Macro Trends From Industry CEOs
Pfizer CEO Albert Bourla, Eli Lilly CEO David Ricks and Seagen CEO David Epstein discussed pressing issues facing the pharmaceutical industry at the recent Galien Forum.